Optimer Pharmaceuticals has fully divested its remaining stake in the US firm's formerly wholly owned Taiwanese subsidiary Optimer Biotechnology Inc (OBI), as part of an ongoing effort to streamline operations and raise funds.
As of 30 June Optimer held a non-controlling 43.6% interest in OBI, but said that it would realise gross proceeds...
Welcome to Scrip
Create an account to read this article
Already a subscriber?